Genentech rejects Roche bid
Friday, 15 August, 2008
A special committee of US biotechnology giant Genentech’s board of directors has rejected a proposal by Swiss pharma Roche to buy out the company for US$43.7 billion.
Roche, which already owns 56 per cent of Genentech, was offering $89 per share for the remaining 44 per cent.
The Genentech directors said the offer undervalued the company but would consider a new proposal at a price it considered worthy.
Genentech’s stocks were trading on the New York Stock Exchange at close to $100 this week.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
